Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
复制标题
DOI：
10.1093/pm/pnaa303
复制
发表时间：
2020-10-01
期刊：
影响因子：
--
通讯作者：
Pelegrini A
中科院分区：
文献类型：
--
作者：
Chaves C;Bittencourt PCT;Pelegrini A
确定富含四氢大麻酚 (THC) 的大麻油对纤维肌痛患者的症状和生活质量的益处。进行了为期八周的双盲、随机、安慰剂对照临床试验，以确定富含 THC 的大麻油（24.44 mg/mL 的 THC 和 0.51 mg/mL 的大麻二酚 [CBD]）对 17 名患有纤维肌痛的妇女的症状和生活质量的益处，这些妇女居住在巴西弗洛里亚诺波利斯市社会经济地位较低且暴力发生率较高的社区。初始剂量为每天一滴（约 1.22 毫克 THC 和 0.02 毫克 CBD），随后根据症状增加剂量。纤维肌痛影响问卷 (FIQ) 在干预前后以及八周内的五次就诊中进行了应用。各组之间的基线 FIQ 评分没有显着差异。然而，干预后，与安慰剂组相比，大麻组的 FIQ 评分显着下降（P = 0.005），与大麻组基线评分相比也显着下降。 （P < 0.001）。通过分析 FIQ 上的单独项目，大麻组在“感觉良好”、“疼痛”、“做工作”和“疲劳”得分方面表现出显着改善。干预后，安慰剂组的“抑郁”评分显着改善。没有出现无法忍受的不良反应。植物大麻素是一种低成本且耐受性良好的疗法，可减轻纤维肌痛患者的症状并提高其生活质量。未来的研究仍需要评估长期效益，并且必须对不同品种的大麻素与洗脱期相关的研究进行研究，以增强我们对大麻在这种健康状况下的作用的了解。
To determine the benefit of a tetrahydrocannabinol (THC)-rich cannabis oil on symptoms and quality of life of fibromyalgia patients. A double-blind, randomized, placebo-controlled clinical trial was conducted for eight weeks to determine the benefit of a THC-rich cannabis oil (24.44 mg/mL of THC and 0.51 mg/mL of cannabidiol [CBD]) on symptoms and quality of life of 17 women with fibromyalgia, residents of a neighborhood with a low socioeconomic profile and a high incidence of violence in the city of Florianopolis, Brazil. The initial dose was one drop (∼1.22 mg of THC and 0.02 mg of CBD) a day with subsequent increases according to symptoms. The Fibromyalgia Impact Questionnaire (FIQ) was applied at pre- and postintervention moments and in five visits over eight weeks. There were no significant differences on baseline FIQ score between groups. However, after the intervention, the cannabis group presented a significant decrease in FIQ score in comparison with the placebo group (P = 0.005) and in comparison with cannabis group baseline score. (P < 0.001). Analyzing isolated items on the FIQ, the cannabis group presented significant improvement on the “feel good,” “pain,” “do work,” and “fatigue” scores. The placebo group presented significant improvement on the “depression” score after intervention. There were no intolerable adverse effects. Phytocannabinoids can be a low-cost and well-tolerated therapy to reduce symptoms and increase the quality of life of patients with fibromyalgia. Future studies are still needed to assess long-term benefits, and studies with different varieties of cannabinoids associated with a washout period must be done to enhance our knowledge of cannabis action in this health condition.
登录
查看更多内容
重新考虑的临床内源性大麻素缺乏症：当前的研究支持偏头痛，纤维肌痛，肠易激和其他耐药综合症的理论。
影响因子：
3.8
作者：
Russo EB
通讯作者：
Russo EB
影响因子：
3.4
作者：
Habib, George;Artul, Suheil
通讯作者：
Artul, Suheil
影响因子：
5.9
作者：
Bennett, RA;Kamin, M;Rosenthal, N
通讯作者：
Rosenthal, N
影响因子：
5.9
作者：
Arnold, LM;Hess, EV;Keck, PE
通讯作者：
Keck, PE
影响因子：
4
作者：
Skrabek, Ryan Quinlan;Gallmova, Lena;Perry, Daryl
通讯作者：
Perry, Daryl